Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Classical hematology 1

Conditions

Lung Neoplasms 4Anemia 4Carcinoma, Non-Small-Cell Lung 3Neoplasms 2Small Cell Lung Carcinoma 1Pleural Effusion, Malignant 1Pleural Effusion 1Neutropenia 1Multiple Myeloma 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Drug-Related Side Effects and Adverse Reactions 1Breast Neoplasms 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

Amifostine 7Radiotherapy 6Cisplatin 6Paclitaxel 4Etoposide 4Carboplatin 3Filgrastim 2Docetaxel 2sargramostim 1pegfilgrastim 1Vitamin E 1Topotecan 1Tocopherols 1Taxes 1Radiation 1Isotretinoin 1Epoetin Alfa 1Darbepoetin alfa 1Cyclophosphamide 1Bevacizumab 12,2'-dithiodiethanesulfonic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Drug-Related Side Effects and Adverse Reactions × Darbepoetin alfa × Thoracic × Clear all
NCT00077311 2016-06-30

Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Alliance for Clinical Trials in Oncology

Phase 2 Completed
160 enrolled
Classical hematologyThoracic

Adenocarcinoma of Lung, Anemia, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neutropenia, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡